Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

83 Share or save for quick reference. When something as big as the Super Bowl is coming up soon, it can be hard to stay focused. This is especially true for families that are die hard sports fans, or ...

We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Melanie Pinola and ...

Discover how to effortlessly create stunning, interactive charts with Syncfusion in .NET MAUI. Enhance your mobile and desktop applications with powerful data visualization features using this ...

Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...

Cartesian is among the leaders in a push by drugmakers to develop cell therapies for autoimmune conditions. Like Kyverna Therapeutics, Cabaletta Bio and many others, the company aims to show that a ...

We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Melanie Pinola I was in ...

Moving an object from one location to another—picking and placing—is an ideal application for industrial robots due to the robots’ repeatability, throughput and favorable return on investment. It is ...